MaxCyte, Inc. Common Stock (MXCT) — Analysis Summary
MaxCyte, Inc. Common Stock (MXCT) has a market cap of $102.69M with year-over-year revenue growth of -5.7%. Net margin stands at -213.0%. The stock trades at a P/E ratio of -2.9.
Key Takeaways
- Revenue changed -5.7% year-over-year
- Net margin of -213.0%
- P/E ratio of -2.9
Compared to other companies in the SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH sector, MXCT posted revenue growth of -5.7% and trades at a P/E of -2.9.
MaxCyte, Inc. Common Stock (MXCT)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -222.0% — severe operating losses
Net margin at -189.3% — losses exceed revenue (possible one-time charges)
Revenue declined 10.2% vs the prior period.
The latest filing shows negative free cash flow.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Employees
91
Headquarters
ROCKVILLE, MD
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.